{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:05:53Z","timestamp":1792292753530,"version":"4.4.0"},"reference-count":25,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12,31]]},"abstract":"<jats:p>Bladder symptoms such as urinary urgency, frequency, and incontinence are common in people with multiple sclerosis (MS). These symptoms, which often result from neurogenic detrusor overactivity (NDO), can have a major impact on patients' day-to-day lives. However, in many cases they are over-looked in the clinical management of MS. The objective of this study was to develop and validate a reliable, sensitive, and specific screening tool for patients with bladder problems related to MS. We performed a literature review and then conducted a content validation study followed by a multisite observational study of a new screening tool, the Actionable Bladder Symptom Screening Tool (ABSST). All ABSST domains as well as the total score met the threshold for good internal consistency (Cronbach \u03b1 \u2265 0.70), with a Cronbach \u03b1 value of 0.95 for the total score and values ranging from 0.85 to 0.90 for the three domains. The validity of the ABSST was demonstrated by high correlation of the domains and total score with the Overactive Bladder Questionnaire Short Form (OAB-q SF) Symptom Severity and Total Health-Related Quality of Life (HRQOL) scores (Spearman correlation coefficient \u2265 0.782). The predictive validity of the ABSST total score to identify patients who might receive a recommendation to see a urologist was strong. This new instrument, which was developed with input from clinicians as well as MS patients, meets the current content validity and psychometric testing thresholds established by the US Food and Drug Administration, with high sensitivity and specificity.<\/jats:p>","DOI":"10.7224\/1537-2073.2012-049","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T11:17:43Z","timestamp":1389007063000},"page":"182-192","source":"Crossref","is-referenced-by-count":39,"title":["Development and Validation of the Actionable Bladder Symptom Screening Tool for Multiple Sclerosis Patients"],"prefix":"10.7224","volume":"15","author":[{"given":"Jack","family":"Burks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chancellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"MacDiarmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Nitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Globe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ib","family":"Odderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalesh","family":"Panicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Perrin","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","reference":[{"key":"2020071713473380600_i1537-2073-15-4-182-b1","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N Engl J Med."},{"key":"2020071713473380600_i1537-2073-15-4-182-b2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet."},{"issue":"3 suppl","key":"2020071713473380600_i1537-2073-15-4-182-b3","first-page":"S9","article-title":"The overactive bladder in multiple sclerosis","volume":"100","author":"Fingerman","year":"2000","journal-title":"J Am Osteopath Assoc."},{"key":"2020071713473380600_i1537-2073-15-4-182-b4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","article-title":"The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines","volume":"13","author":"de Seze","year":"2007","journal-title":"Mult Scler."},{"key":"2020071713473380600_i1537-2073-15-4-182-b5","first-page":"470","article-title":"A UK consensus on the management of the bladder in multiple sclerosis","volume":"80","author":"Fowler","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"2020071713473380600_i1537-2073-15-4-182-b6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458504ms1063oa","article-title":"An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis","volume":"10","author":"Brady","year":"2004","journal-title":"Mult Scler."},{"key":"2020071713473380600_i1537-2073-15-4-182-b7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-200363020-00003","article-title":"Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies","volume":"63","author":"DasGupta","year":"2003","journal-title":"Drugs."},{"key":"2020071713473380600_i1537-2073-15-4-182-b8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.juro.2009.12.029","article-title":"Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry","volume":"183","author":"Mahajan","year":"2010","journal-title":"J Urol."},{"issue":"11 suppl","key":"2020071713473380600_i1537-2073-15-4-182-b9","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care."},{"issue":"5 suppl 1","key":"2020071713473380600_i1537-2073-15-4-182-b10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)01544-3","article-title":"Bladder afferents and their role in the overactive bladder","volume":"59","author":"Fowler","year":"2002","journal-title":"Urology."},{"key":"2020071713473380600_i1537-2073-15-4-182-b11","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0022-5347(06)00258-8","article-title":"Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity","volume":"175","author":"Giannantoni","year":"2006","journal-title":"J Urol."},{"issue":"suppl","key":"2020071713473380600_i1537-2073-15-4-182-b12","first-page":"181A","article-title":"Botulinum toxin injection into the bladder wall decreases acetylcholine (ACH) and norepinephrine (NE) release; potential treatment for the overactive bladder","volume":"163","author":"Franks","year":"2000","journal-title":"J Urol."},{"key":"2020071713473380600_i1537-2073-15-4-182-b13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J Urol."},{"key":"2020071713473380600_i1537-2073-15-4-182-b14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur Urol."},{"key":"2020071713473380600_i1537-2073-15-4-182-b15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00345-009-0466-1","article-title":"Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany","volume":"28","author":"Wefer","year":"2010","journal-title":"World J Urol."},{"key":"2020071713473380600_i1537-2073-15-4-182-b16","volume-title":"Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"US Department of Health and Human Services, Food and Drug Administration","year":"2009"},{"key":"2020071713473380600_i1537-2073-15-4-182-b17","article-title":"An overactive bladder symptom and quality-of-life short form: development of the Overactive Bladder Questionnaire Short Form (OAB-q SF)","author":"Coyne"},{"key":"2020071713473380600_i1537-2073-15-4-182-b18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res."},{"key":"2020071713473380600_i1537-2073-15-4-182-b19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02310555","article-title":"Coefficient alpha and the internal structure of tests","volume":"16","author":"Cronbach","year":"1951","journal-title":"Psychometrika."},{"key":"2020071713473380600_i1537-2073-15-4-182-b20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/009286150203600127","article-title":"Patient-reported outcomes: the example of health-related quality of life\u2014a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process","volume":"36","author":"Chassany","year":"2002","journal-title":"Drug Inform J."},{"key":"2020071713473380600_i1537-2073-15-4-182-b21","first-page":"248","article-title":"The assessment of reliability","author":"Nunnally","year":"1994","journal-title":"Psychometric Theory"},{"key":"2020071713473380600_i1537-2073-15-4-182-b22","article-title":"Interpreting diagnostic tests","author":"Tape","year":"2012"},{"key":"2020071713473380600_i1537-2073-15-4-182-b23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/rheumatology\/40.5.528","article-title":"A brief screening tool for knee pain in primary care: 1. Validity and reliability","volume":"40","author":"Jinks","year":"2001","journal-title":"Rheumatology (Oxford)."},{"key":"2020071713473380600_i1537-2073-15-4-182-b24","first-page":"469","article-title":"Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire","volume":"27","author":"Ibrahim","year":"2009","journal-title":"Clin Exp Rheumatol."},{"key":"2020071713473380600_i1537-2073-15-4-182-b25","volume-title":"Epidemiology: An Introductory Text","author":"Mausner","year":"1974"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/15\/4\/182\/2553105\/1537-2073_2012-049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/15\/4\/182\/2553105\/1537-2073_2012-049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:11:42Z","timestamp":1752786702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/development-and-validation-of-the-actionable-bladder-symptom-screening-tool-for-multiple-sclerosis-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,31]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12,31]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2012-049","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12,31]]}}}